
roe base ttm core earn end
quarterli figur may add annual figur due round
plan acquisit
revenu figur exclud recent divest busi plan
largest consum product compani
world featur brand
gener annual sale billion popular
olay oral-b pamper panten tide vick
compani conduct oper countri
net sale rose billion margin
street consensu figur slightli shi
estim organ sale rose
previou quarter due mostli higher
volum overal price neg foreign
exchang boost report sale figur
earn per share rose margin
expect gross margin
point due higher commod cost foreign
point lower tax rate benefit share
repurchas help ep calcul ep
exceed year ago figur
street consensu estim
pg also announc acquisit compani
agre purchas consum health busi
german-bas merck kgaa billion
line add busi growth profil mid
upper singl digit percentag pg
exist busi deal expect close
sometim june year end
outlook
organ sale growth expect come low
end previous state rang all-in
sale growth remain ep growth
expect rang bit precis
previou rang fine-tun
estim minor chang
earn dividend like increas
year yet busi rebound slower
unfold expect due macro industri
challeng yet factor pg recent
announc acquisit lower two-year
price target per share reflect revis
margin stock valuat assumpt
suitabl rate
note import disclosur page
note analyst certif page
consolid statement earn figur million except percentag per share data
product sold
net earn contin oper
non-controlling interest
net earn attrib pg
report contin oper
net sale
net earn contin oper
segment highlight pg deliv increas organ sale compar
gain previou quarter reflect slight volum growth neg price impact
pg major busi segment all-in sale rose billion slightli
street consensu expect gain reflect benefit foreign exchang compar
previou quarter benefit
compani largest segmentfabr carepost gain organ sale
volum benefit recent product innov market support particularli pleas
second consecut quarterli sale gain beauti segment
scrutin lacklust perform past year premium product sk-ii skin care brand
innov olay skin care contribut factor segment health also post
decent result benefit notabl cough/cold season
neg aspect quarter view includ babi segment increas
competit activ trade inventori reduct groom segment on-going heighten
competit environ prompt past price reduct reach one year
gross margin exclud currenc fluctuat non-recurring item add perspect
core busi trend basi gross margin declin basi point product save
off-set commod cost increas shift geograph product mix higher
transport cost neg price previou quarter measur gross
margin declin basi point anticip gross margin pressur basi yet quit
realiz level
fiscal segment sale margin summari figur million except percentag
volume
acquisit addit report fiscal result pg announc agre acquir
consum busi merck kgaa headquart darmstadt germani purchas price
billion euro equat approxim billion annual sale acquir busi
billion assum regulatori approv transact expect complet
sometim pg period financi guidanc purpos mid-point date
assum would repres roughli million sale neutral ep impact
ep accret
busi acquir includ numer product muscle/joint pain cold
headach health/diet supplement physic mobil categori major market includ europ
latin america asia demonstr growth mid upper-singl digit percentag exce
exist pg busi profit margin yet incorpor acquisit
financi model prefer wait greater clariti deal potenti close full
acquisit would essenti replac pg current smaller health care joint ventur share profit
teva pharmaceut industri termin juli
financi condit compani balanc sheet remain decent shape view
march cash equival total billion short-term invest avail sale
total anoth billion total debt short-term plu long-term billion
total capit sharehold equiti billion
quarter oper cash flow billion million capit spend
free cash flow billion quarter compani paid billion dividend
spent billion share repurchas
recent board addit mid-decemb pg agre add activist investor nelson
peltz member board director follow close often recalcul
sharehold vote stint began march addit bit surpris us
director ad pg appoint joseph jimenez former ceo novarti ag also effect march
believ peltz pg board/manag team work togeth effect includ
consider peltz idea make pg effici enhanc sharehold valu
also consid addit jimenez posit factor respect busi career
believ two addit strengthen overal qualiti pg board independ
dividend updat april pg rais dividend quarterli rate
per share mark consecut year dividend increas expect continu annual
dividend increas go forward announc time year consid pg dividend
yield current posit invest factor recent yield consum stapl
sector yield
earn outlook addit report result manag updat financi
guidanc fiscal year end june highlight outlook includ
organ sale expect rise low end previous given rang
all-in sale expect chang previou guidanc
ep includ currenc impact exclud non-recurring item expect increas
moder higher previous issu guidanc rang
would repres project ep rang
updat financi model see exhibit updat sale margin assumpt
tax rate share count lead neglig chang earn estim project core
ep previou estim nearli figur assum
near reduct weight averag share count due dual impact share retir
result recent transact inc beauti brand divestitur on-going share
repurchas part pg exist buy-back author
expect year similar current year roughli revenu growth
core ep growth fine-tun assumpt behind metric expect
effici recent portfolio transform yet spend produc innov product
line defend market share
believ much appeal pg share compani outlook relat longer
term begin compani product portfolio transform like continu
view acquisit mental possibl back pictur aggress spend product
innov advertis could move organ sale growth recent level also overal cost
structur continu tighten share count continu declin due on-going
repurchas dictat free cash flow gener believ long-term ep growth could mid
upper single-digit level fairli consist basi occasion reach low double-digit
valuat stock price weak year calendar ytd period pg
share becom cheaper price-to-earnings basi pg share trade approxim
estim forward earn time last research report date follow
fiscal result forward multipl median forward multipl pg
past fifteen year reflect gener rise valuat past nine year past year
exclud similar consum stapl sector valuat lesser extent
addit pg share current trade forward multipl
compar histor premium past fifteen year pg forward multipl current
repres slight discount rel consum stapl forward multipl
mean premium past fifteen year
opinion past year challeng pg consid heavi lift
phase pg product portfolio transform behind past year chang
compani relat product portfolio divestitur oper execut effici
improv manag ceo board size composit past two
year compani divest discontinu consolid brand combin
brand repres pg recent annual sale annual profit
believ second part effect portfolio transform ad appeal product
categori merck kgaa consum health busi good exampl global
footprint favor industri outlook above-averag growth margin profil addit
believ pend purchas could sign new sentiment pg one put
offens rather defens proactiv pursu addit product profil higher potenti
believ upsid potenti pg financi oper perform includ
measur market share posit product innov product qualiti profit margin
earn on-going cost save program continu invest busi order
maintain grow market share remain prioriti compani
stock believ pg share primarili influenc earn growth
expect modest level near term longer term believ price
meaning tool market share posit could boost product innov product
portfolio could sport higher margin also believ acquisit could potenti sourc growth
rate pg long-term buy believ potenti improv current busi
segment pend consum health care acquisit new voic board below-averag
stock valuat above-averag dividend yield meaning factor consid view
execut expect current low seemingli put pg share favor
investor believ present opportun patient longer term investor
reduc two year price target per share basi lower
valuat assumpt slightli lower estim forward ep two year believ
lower valuat assumpt justifi competit environ versu brand privat label
product potenti expens headwind integr recent announc acquisit could
also present challeng ad debt uncertainti new product new market
assum price-to-earnings multipl expect forward earn two year lower
assumpt last report depress current multipl
five-year fifteen-year median forward multipl respect
two-year target reflect potenti total return includ dividend
annual basi advoc two year invest time horizon believ allow pg time
make meaning invest busi launch new product refin product portfolio
integr plan acquisit improv margin profit level
suitabl suitabl rate scale conserv
aggress reflect factor pg larg market capit divers product portfolio larg
market share posit numer billion-dollar brand solid histori earn dividend growth
time healthi financi condit
risk world-wide consum product compani numer factor could
affect oper possibl stock price includ chang consum demand
compani product competit price pressur chang input cost commod price
raw materi labor risk associ intern oper exchang rate
fluctuat geopolit risk relationship retail trade custom global economi
recent divestitur non-cor busi anoth key invest factor repres
consider chang compani profil also note recent chang board director
includ two new member one consid activist investor demonstr histori
advoc chang board compani
consolid statement oper figur million except percentag per share dat
product sold
net earn cont oper
less earn attribut
net earn attrib pg
report contin oper
net sale
net earn cont oper
dividend paid fy per share
note continu oper exclud pet batteri certain beauti busi present
year addit plan acquisit reflect model
compani report hilliard lyon estim note june fiscal year
addit inform avail upon request
price stock mention
jeffrey thomison herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
